Planned intervention: On Thursday 19/09 between 05:30-06:30 (UTC), Zenodo will be unavailable because of a scheduled upgrade in our storage cluster.
Published October 18, 2023 | Version v1
Journal article Open

Sensor-integrated brain-on-a-chip platforms: Improving thepredictive validity in neurodegenerative research

  • 1. TU Wien
  • 2. Vienna University of Technology

Description

Affecting millions of individuals worldwide, neurodegenerative diseases (NDDs) pose a significant and growing health concern in people over the age of 60 years. Contributing to this trend are the steady increase in the aging population coupled with a persistent lack of disease-altering treatment strategies targeting NDDs. The absence of efficient therapeutics can be attributed to high failure rates in clinical trials and the ineptness of animal models in preceding preclinical studies. To that end, in recent years, significant research effort has been dedicated to the development of human cell-based preclinical disease models characterized by a higher degree of predictive validity. However, a key requirement of any in vitro model constitutes the precise knowledge and replication of the target tissues' (patho-)physiological microenvironment. Herein, microphysiological systems have demonstrated superiority over conventional static 2D/3D in vitro cell culture systems, as they allow for the emulation and continuous monitoring of the onset, progression, and remission of disease-associated phenotypes. This review provides an overview of recent advances in the field of NDD research using organ-on-a-chip platforms. Specific focus is directed toward non-invasive sensing strategies encompassing electrical, electrochemical, and optical sensors. Additionally, promising on- and integrable off-chip sensing strategies targeting key analytes in NDDs will be presented and discussed in detail.

Files

Bioengineering Transla Med - 2023 - Spitz - Sensor‐integrated brain‐on‐a‐chip platforms Improving the predictive.pdf

Additional details

Funding

NANOFACTS – Networking Activities for Nanotechnology-Facilitated Cancer Theranostics 952259
European Commission